AstraZeneca (NASDAQ:AZN) Upgraded by Deutsche Bank Aktiengesellschaft to Hold Rating

Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca (NASDAQ:AZN) from a sell rating to a hold rating in a report released on Wednesday morning, MarketBeat reports.

Other research analysts have also recently issued research reports about the company. TD Cowen boosted their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, AstraZeneca presently has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Price Performance

Shares of NASDAQ:AZN opened at $64.49 on Wednesday. The company has a market cap of $199.96 billion, a P/E ratio of 31.15, a P/E/G ratio of 1.18 and a beta of 0.47. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69. AstraZeneca has a 52 week low of $60.47 and a 52 week high of $87.68. The business has a fifty day simple moving average of $77.07 and a 200-day simple moving average of $78.51.

Hedge Funds Weigh In On AstraZeneca

Several institutional investors have recently made changes to their positions in the stock. McClarren Financial Advisors Inc. boosted its position in shares of AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after buying an additional 247 shares during the period. GHP Investment Advisors Inc. bought a new position in AstraZeneca during the second quarter valued at about $26,000. Capital Performance Advisors LLP acquired a new stake in AstraZeneca in the 3rd quarter valued at about $28,000. Pathway Financial Advisers LLC acquired a new position in shares of AstraZeneca in the 1st quarter worth approximately $29,000. Finally, RFP Financial Group LLC lifted its stake in AstraZeneca by 56.3% during the first quarter. RFP Financial Group LLC now owns 494 shares of the company’s stock valued at $33,000 after purchasing an additional 178 shares during the last quarter. 20.35% of the stock is owned by institutional investors.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.